 | • レポートコード：MRC2307A0095 • 出版社/出版日：Transparency Market Research / 2023年5月 • レポート形態：英文、PDF、241ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本報告書は、世界の臓器移植拒絶反応治療薬市場規模が、2023年の49億ドルから予測期間中、年平均3.9％で成長し、2031年には70億ドルに達すると予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、市場分析＆予測、薬物クラス別（抗体、代謝拮抗薬、カルシニューリン阻害薬、mTOR阻害薬、ステロイド）分析、移植種類別（腎臓、肝臓、心臓、肺、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの構成でまとめています。なお、当市場の主要企業には、Pfizer, Inc.、Astellas Pharma, Inc.、Novartis AG、F. Hoffmann-La Roche Ltd.、Sanofi、Bristol-Myers Squibb Company、GlaxoSmithKline plc、AbbVie, Inc.、Hansa Biopharma、WOCKHARDT、Viatris, Inc.、Glenmark、Biocon、Hikma Pharmaceuticals plc、Teva Pharmaceutical U.S.A Inc.、Zydus Pharmaceuticals, Inc.などがあります。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・市場分析＆予測 ・世界の臓器移植拒絶反応治療薬市場規模：薬物クラス別 - 抗体の市場規模 - 代謝拮抗薬の市場規模 - カルシニューリン阻害薬の市場規模 - mTOR阻害薬の市場規模 - ステロイドの市場規模 ・世界の臓器移植拒絶反応治療薬市場規模：移植種類別 - 腎臓移植の市場規模 - 肝臓移植の市場規模 - 心臓移植の市場規模 - 肺移植の市場規模 - その他移植種類の市場規模 ・世界の臓器移植拒絶反応治療薬市場規模：流通チャンネル別 - 病院薬局チャンネルの市場規模 - 小売薬局チャンネルの市場規模 - オンライン薬局チャンネルの市場規模 ・世界の臓器移植拒絶反応治療薬市場規模：地域別 - 北米の臓器移植拒絶反応治療薬市場規模 - ヨーロッパの臓器移植拒絶反応治療薬市場規模 - アジア太平洋の臓器移植拒絶反応治療薬市場規模 - 中南米の臓器移植拒絶反応治療薬市場規模 - 中東・アフリカの臓器移植拒絶反応治療薬市場規模 ・競争状況 |
Organ Transplant Rejection Medication Market – Scope of Report
TMR’s report on the global Organ Transplant Rejection Medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Organ Transplant Rejection Medication market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Organ Transplant Rejection Medication market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Organ Transplant Rejection Medication market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Organ Transplant Rejection Medication market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Organ Transplant Rejection Medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Organ Transplant Rejection Medication market.
The report delves into the competitive landscape of the global Organ Transplant Rejection Medication market. Key players operating in the global Organ Transplant Rejection Medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Organ Transplant Rejection Medication market profiled in this report.
Key Questions Answered in Global Organ Transplant Rejection Medication Market Report
• What is the sales/revenue generated by Organ Transplant Rejection Medication across all regions during the forecast period?
• What are the opportunities in the global Organ Transplant Rejection Medication market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Organ Transplant Rejection Medication Market – Research Objectives and Research Approach
The comprehensive report on the global Organ Transplant Rejection Medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Organ Transplant Rejection Medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Organ Transplant Rejection Medication market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Organ Transplant Rejection Medication Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Current Global Scenario: Organ Donation for Transplantation
5.2. Key Product/Brand Analysis
5.3. Pipeline Analysis
5.4. COVID-19 Impact Analysis
6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Antibodies
6.3.1.1. Thymoglobulin
6.3.1.2. Alemtuzumab
6.3.1.3. Belatacept
6.3.1.4. Muromonab-CD3
6.3.1.5. Basiliximab
6.3.1.6. Eculizumab
6.3.2. Antimetabolites
6.3.2.1. Azathioprine
6.3.2.2. Mycophenolate Mofetil
6.3.2.3. Mycophenolate sodium, MPA
6.3.3. Calcineurin Inhibitors
6.3.3.1. Cyclosporine
6.3.3.2. Tacrolimus
6.3.4. mTOR Inhibitors
6.3.4.1. Sirolimus
6.3.4.2. Everolimus
6.3.5. Steroids
6.3.5.1. Prednisolone
6.3.5.2. Methylprednisolone
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Transplant Type, 2017-2031
7.3.1. Kidney
7.3.2. Liver
7.3.3. Heart
7.3.4. Lung
7.3.5. Pancreas
7.3.6. Others
7.4. Market Attractiveness Analysis, by Transplant Type
8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Organ Transplant Rejection Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. Antibodies
10.2.1.1. Thymoglobulin
10.2.1.2. Alemtuzumab
10.2.1.3. Belatacept
10.2.1.4. Muromonab-CD3
10.2.1.5. Basiliximab
10.2.1.6. Eculizumab
10.2.2. Antimetabolites
10.2.2.1. Azathioprine
10.2.2.2. Mycophenolate Mofetil
10.2.2.3. Mycophenolate sodium, MPA
10.2.3. Calcineurin Inhibitors
10.2.3.1. Cyclosporine
10.2.3.2. Tacrolimus
10.2.4. mTOR Inhibitors
10.2.4.1. Sirolimus
10.2.4.2. Everolimus
10.2.5. Steroids
10.2.5.1. Prednisolone
10.2.5.2. Methylprednisolone
10.3. Market Value Forecast, by Transplant Type, 2017-2031
10.3.1. Kidney
10.3.2. Liver
10.3.3. Heart
10.3.4. Lung
10.3.5. Pancreas
10.3.6. Others
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Transplant Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Antibodies
11.2.1.1. Thymoglobulin
11.2.1.2. Alemtuzumab
11.2.1.3. Belatacept
11.2.1.4. Muromonab-CD3
11.2.1.5. Basiliximab
11.2.1.6. Eculizumab
11.2.2. Antimetabolites
11.2.2.1. Azathioprine
11.2.2.2. Mycophenolate Mofetil
11.2.2.3. Mycophenolate sodium, MPA
11.2.3. Calcineurin Inhibitors
11.2.3.1. Cyclosporine
11.2.3.2. Tacrolimus
11.2.4. mTOR Inhibitors
11.2.4.1. Sirolimus
11.2.4.2. Everolimus
11.2.5. Steroids
11.2.5.1. Prednisolone
11.2.5.2. Methylprednisolone
11.3. Market Value Forecast, by Transplant Type, 2017-2031
11.3.1. Kidney
11.3.2. Liver
11.3.3. Heart
11.3.4. Lung
11.3.5. Pancreas
11.3.6. Others
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Transplant Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Antibodies
12.2.1.1. Thymoglobulin
12.2.1.2. Alemtuzumab
12.2.1.3. Belatacept
12.2.1.4. Muromonab-CD3
12.2.1.5. Basiliximab
12.2.1.6. Eculizumab
12.2.2. Antimetabolites
12.2.2.1. Azathioprine
12.2.2.2. Mycophenolate Mofetil
12.2.2.3. Mycophenolate sodium, MPA
12.2.3. Calcineurin Inhibitors
12.2.3.1. Cyclosporine
12.2.3.2. Tacrolimus
12.2.4. mTOR Inhibitors
12.2.4.1. Sirolimus
12.2.4.2. Everolimus
12.2.5. Steroids
12.2.5.1. Prednisolone
12.2.5.2. Methylprednisolone
12.3. Market Value Forecast, by Transplant Type, 2017-2031
12.3.1. Kidney
12.3.2. Liver
12.3.3. Heart
12.3.4. Lung
12.3.5. Pancreas
12.3.6. Others
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Transplant Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Antibodies
13.2.1.1. Thymoglobulin
13.2.1.2. Alemtuzumab
13.2.1.3. Belatacept
13.2.1.4. Muromonab-CD3
13.2.1.5. Basiliximab
13.2.1.6. Eculizumab
13.2.2. Antimetabolites
13.2.2.1. Azathioprine
13.2.2.2. Mycophenolate Mofetil
13.2.2.3. Mycophenolate sodium, MPA
13.2.3. Calcineurin Inhibitors
13.2.3.1. Cyclosporine
13.2.3.2. Tacrolimus
13.2.4. mTOR Inhibitors
13.2.4.1. Sirolimus
13.2.4.2. Everolimus
13.2.5. Steroids
13.2.5.1. Prednisolone
13.2.5.2. Methylprednisolone
13.3. Market Value Forecast, by Transplant Type, 2017-2031
13.3.1. Kidney
13.3.2. Liver
13.3.3. Heart
13.3.4. Lung
13.3.5. Pancreas
13.3.6. Others
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Transplant Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Antibodies
14.2.1.1. Thymoglobulin
14.2.1.2. Alemtuzumab
14.2.1.3. Belatacept
14.2.1.4. Muromonab-CD3
14.2.1.5. Basiliximab
14.2.1.6. Eculizumab
14.2.2. Antimetabolites
14.2.2.1. Azathioprine
14.2.2.2. Mycophenolate Mofetil
14.2.2.3. Mycophenolate sodium, MPA
14.2.3. Calcineurin Inhibitors
14.2.3.1. Cyclosporine
14.2.3.2. Tacrolimus
14.2.4. mTOR Inhibitors
14.2.4.1. Sirolimus
14.2.4.2. Everolimus
14.2.5. Steroids
14.2.5.1. Prednisolone
14.2.5.2. Methylprednisolone
14.3. Market Value Forecast, by Transplant Type, 2017-2031
14.3.1. Kidney
14.3.2. Liver
14.3.3. Heart
14.3.4. Lung
14.3.5. Pancreas
14.3.6. Others
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Transplant Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Astellas Pharma, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Sanofi
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Bristol-Myers Squibb Company
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. GlaxoSmithKline plc
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. AbbVie, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Hansa Biopharma
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. WOCKHARDT
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.2. Product Portfolio
15.3.10.3. Business Strategies
15.3.10.4. Recent Developments
15.3.11. Viatris, Inc.
15.3.11.1. Company Overview
15.3.11.2. Financial Overview
15.3.11.3. Product Portfolio
15.3.11.4. Business Strategies
15.3.11.5. Recent Developments
15.3.12. Glenmark
15.3.12.1. Company Overview
15.3.12.2. Financial Overview
15.3.12.3. Product Portfolio
15.3.12.4. Business Strategies
15.3.12.5. Recent Developments
15.3.13. Biocon
15.3.13.1. Company Overview
15.3.13.2. Financial Overview
15.3.13.3. Product Portfolio
15.3.13.4. Business Strategies
15.3.13.5. Recent Developments
15.3.14. Hikma Pharmaceuticals plc
15.3.14.1. Company Overview
15.3.14.2. Financial Overview
15.3.14.3. Product Portfolio
15.3.14.4. Business Strategies
15.3.14.5. Recent Developments
15.3.15. Teva Pharmaceutical U.S.A Inc.
15.3.15.1. Company Overview
15.3.15.2. Financial Overview
15.3.15.3. Product Portfolio
15.3.15.4. Business Strategies
15.3.15.5. Recent Developments
15.3.16. Zydus Pharmaceuticals, Inc.
15.3.16.1. Company Overview
15.3.16.2. Financial Overview
15.3.16.3. Product Portfolio
15.3.16.4. Business Strategies
15.3.16.5. Recent Developments
Table 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 11: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 12: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 13: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 14: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 15: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 16: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 17: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 18: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017‒2031
Table 19: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 20: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 21: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 22: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 23: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 24: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 25: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 26: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 27: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 28: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 29: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 30: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 31: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 32: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 33: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 34: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 35: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 36: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 37: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 38: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 39: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 40: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 41: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 42: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 43: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 44: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 45: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 46: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 47: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 48: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 49: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 50: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 51: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 52: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 53: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 54: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031